Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 11/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
| ▸ | HTR7 | P34969 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15538190 | 0.86 | HTR7 (0.75) | USP2CYP1A2HSD17B10MAPK1SMN1; SMN2 | |
| SCHEMBL5239356 | 0.84 | MEN1 (0.68) | USP2CYP1A2HSD17B10MAPK1SMN1; SMN2 | |
| SCHEMBL631962 | 0.84 | ALDH1A1 (0.69) | USP2CYP1A2MAPK1HTR1AHTR7 | |
| SCHEMBL13164531 | 0.83 | USP2 (0.56) | USP2CYP1A2HSD17B10MAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5492248 | 0.82 | ALDH1A1 (0.67) | USP2CYP1A2MAPK1HTR1AHTR7 | |
| SCHEMBL27818822 | 0.81 | CHRNB4 (0.52) | USP2CYP1A2MAPK1SMN1; SMN2CYP2D6 | |
| SCHEMBL1458090 | 0.81 | HTR1A (0.73) | SMN1; SMN2HTR1AHTR7MEN1KMT2A | |
| SCHEMBL5399904 | 0.81 | DRD2 (0.56) | USP2CYP1A2MAPK1SMN1; SMN2HTR1A | |
| SCHEMBL3119833 | 0.81 | ADRA2C (0.59) | USP2CYP1A2MAPK1SMN1; SMN2HTR1A | |
| SCHEMBL8224772 | 0.81 | USP2 (0.51) | USP2CYP1A2HSD17B10MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1701946-B1 | DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME | SANOFI AVENTIS (FR) | 2007-12-19 | — | — | EP | claimed |
| US-20230121721-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2023-04-20 | — | — | US | disclosed |
| US-11530198-B2 | Compositions and methods for treating infections | Vyera Pharmaceuticals, LLC (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3875452-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2021-09-08 | — | — | EP | disclosed |
| US-20200407345-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS | TURING PHARMACEUTICALS LLC | 2020-12-31 | — | — | US | disclosed |
| US-10774073-B2 | Compositions and methods for treating infections | Vyera Pharmaceuticals, LLC (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200270233-A1 | DHFR INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC | 2020-08-27 | — | — | US | disclosed |
| US-20190077794-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS | Vyera Pharmaceuticals, LLC (US) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121721-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LIPA | USP2 979/4885CYP1A2 678/4885HSD17B10 234/4885 |
| US-20190077794-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS | DHFR, DHODH, QDPR | USP2 3943/4885CYP1A2 793/4885HSD17B10 925/4885 |
| US-20200407345-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS | DHFR, DHODH, QDPR | USP2 3943/4885CYP1A2 793/4885HSD17B10 925/4885 |
| US-11530198-B2 | Compositions and methods for treating infections | DHFR, DHODH, QDPR | USP2 3943/4885CYP1A2 793/4885HSD17B10 925/4885 |
| US-20200270233-A1 | DHFR INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | DHFR, DHODH, FPGS | USP2 3027/4885CYP1A2 874/4885HSD17B10 1064/4885 |
| US-10774073-B2 | Compositions and methods for treating infections | DHFR, DHODH, QDPR | USP2 3943/4885CYP1A2 793/4885HSD17B10 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.